APLI.F Stock Overview A biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Appili Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Appili Therapeutics Historical stock prices Current Share Price CA$0.026 52 Week High CA$0.05 52 Week Low CA$0.013 Beta 0.95 1 Month Change 6.02% 3 Month Change 15.79% 1 Year Change -0.38% 3 Year Change -69.12% 5 Year Change n/a Change since IPO -98.01%
Recent News & Updates Shares of Appili Therapeutics to Delist from Toronto Stock Exchange Following Completion of the Transaction Nov 20
Appili Therapeutics Inc. Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Nov 01
Appili Therapeutics Inc., Annual General Meeting, Sep 17, 2024 Jul 26 Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. (TSX:APLI) for $6.7 million. Apr 03
Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension Sep 26 See more updates Shares of Appili Therapeutics to Delist from Toronto Stock Exchange Following Completion of the Transaction Nov 20
Appili Therapeutics Inc. Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission Nov 01
Appili Therapeutics Inc., Annual General Meeting, Sep 17, 2024 Jul 26 Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. (TSX:APLI) for $6.7 million. Apr 03
Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension Sep 26
Appili Therapeutics Inc., Annual General Meeting, Sep 27, 2023 Jul 26
Appili Therapeutics Inc. and Saptalis Pharmaceuticals LLC Announce That FDA Accepts the ATI-1501 NDA Feb 09
Appili Therapeutics Inc. Announces Executive Appointments Jan 18
Appili Therapeutics Inc. Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole Jan 14 Appili Therapeutics Inc. Promotes Don Cilla to the Position of Chief Executive Officer
Appili Therapeutics Inc., Annual General Meeting, Sep 22, 2022 Jul 28 Appili Therapeutics Inc. announced that it expects to receive $10 million in funding from Defense Threat Reduction Agency Jun 30
Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million. May 28
Appili Therapeutics Inc. has completed a Composite Units Offering in the amount of CAD 4.5 million. May 27
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis Apr 14 Appili Therapeutics Inc. announced that it expects to receive CAD 4.504032 million in funding from Long Zone Holdings Inc. Mar 30
Appili Therapeutics Inc. Announces Over $10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701 Mar 01
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan/Reeqonus for the Treatment of Mild-to-Moderate COVID-19 Sep 24
Appili Therapeutics Inc. announced that it has received $1 million in funding from FUJIFILM Toyama Chemical Co., Ltd. Sep 21
Appili Therapeutics Inc. Announces Completion of Patient Enrollment for Avigan Reeqonus Viral Shedding Sub- Study for Mild-To-Moderate Covid-19 Patients Sep 20
Appili Therapeutics Inc. announced that it has received CAD 3.395 million in funding from The Lind Partners, LLC Aug 19
Appili Therapeutics Inc. announced that it expects to receive CAD 3.5 million in funding from The Lind Partners, LLC Aug 11
Appili Therapeutics Inc. Expands Preseco Clinical Trial of Avigan®/Reeqonus™ for Mild-To-Moderate Covid-19 Patients into Mexico and Brazil Jun 18
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Inc. Complete its Phase 3 Avigan®/Reeqonustm Trial for Mild- To-Moderate COVID-19 Patients Jun 17
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete its Phase 3 Avigan/Reeqonus Trial for Mild-to-Moderate COVID-19 Patients May 18
Appili Therapeutics Inc. Appoints Rochelle Stenzler as Board of Directors Feb 03
Appili Therapeutics Provides Enrollment Update for Its Phase 3 PRESECO Trial Evaluating the Oral Antiviral Favipiravir as an Early Treatment in COVID-19 Jan 29
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States Dec 03
Appili Therapeutics Inc Announces Initiation of its Phase 3 Post Exposure Prophylaxis for Covid-19 (Pepco) Study to Evaluate Avigan® Tablets (Favipiravir) in the Prevention of Covid-19 Nov 25
Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and Fujifilm in Advancing Avigan Tablets for the Potential Treatment of Covid-19 Nov 02
Appili Therapeutics Inc. Announces Appointment of Don Cilla as Chief Development Officer, Effective November 1, 2020 Oct 30
Appili Therapeutics Inc. Announces Updates for the Continued Development of its ATI-1701 Biodefense Vaccine Program Oct 29 Shareholder Returns APLI.F US Pharmaceuticals US Market 7D 2.6% 0.6% -0.4% 1Y -0.4% 10.0% 24.8%
See full shareholder returns
Return vs Market: APLI.F underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is APLI.F's price volatile compared to industry and market? APLI.F volatility APLI.F Average Weekly Movement 32.4% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: APLI.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APLI.F's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Show more Appili Therapeutics Inc. Fundamentals Summary How do Appili Therapeutics's earnings and revenue compare to its market cap? APLI.F fundamental statistics Market cap US$2.96m Earnings (TTM ) -US$2.50m Revenue (TTM ) US$344.77k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) APLI.F income statement (TTM ) Revenue CA$494.78k Cost of Revenue CA$0 Gross Profit CA$494.78k Other Expenses CA$4.08m Earnings -CA$3.58m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.03 Gross Margin 100.00% Net Profit Margin -724.40% Debt/Equity Ratio -79.5%
How did APLI.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 00:43 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Appili Therapeutics Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Chelsea Stellick iA Capital Markets Douglas Loe Leede Jones Gable Inc Andre Uddin Research Capital Corporation
Show 0 more analysts 
